ASH 2020 | Developments in the mastocytosis field at ASH 2020
Srdan Verstovek, MD, PhD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses key developments in the treatment of aggressive systemic mastocytosis. While it is normally a benign condition, a subgroup of patients experience life-threatening mastocytosis which affects organ function. Recent development of the mutant KIT-targeted therapy, avapritinib is a significant advancement for these patients. Several early trials will be presented at ASH 2020. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Srdan Verstovsek, MD, PhD, has received research support for clinical studies from Incyte, Roche, NS, Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Abbvie, Blueprint Medicines Corp., Novartis, Sierra Oncology, PharmaEssentia, Constellation, Ital Pharma, Protagonist and Kartos.
